Program
Lipid Nanoparticle-encapsulated EBV mRNA Vaccine mRNA-1189
Its studies are mostly in Epstein-Barr Virus Infections, led by Moderna.
Furthest: phase 2, since Dec 1, 20212 company-led studies, 2 open or runningNext primary completion: May 15, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Moderna | 22 open or running | phase 2since Dec 1, 2021 | Dec 1, 2021 | May 15, 2027phase 1 · NCT07478952 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 1, 2021First study: phase 2 study in Epstein-Barr Virus InfectionsFirst studyNCT05164094 · 867 enrolled · United States
- Mar 13, 2026Phase 1 study in Epstein-Barr Virus InfectionsNCT07478952 · 120 planned · Australia
Ahead
- May 15, 2027Primary completion: phase 1 study in Epstein-Barr Virus InfectionsNCT07478952
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A vaccine consisting of a lipid nanoparticle (LNP) encapsulating four messenger RNAs (mRNAs) encoding the Epstein-Barr Virus (EBV) envelope glycoproteins gp42, gp220, gH and gL, ”NCIt, by rule
“Lipid Nanoparticle-encapsulated EBV mRNA Vaccine mRNA-1189”name, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07478952Epstein-Barr Virus Infections · Australia | 1 | Recruiting | May 15, 2027 | 120 |
| NCT05164094Epstein-Barr Virus Infections · United States | 2 | Active, not recruiting | Oct 5, 2026 | 867 |
How it is read
Names in the registry
- “mRNA-1189”, 2 entries
Conditions, from the studies’ own filings
- Epstein-Barr Virus Infections, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.